糖尿病性黄斑水肿治疗中康柏西普玻璃体内注射的应用效果  

Application Effect of Intravitreal Injection of Conbercept in the Treatment of Diabetic Macular Edema

作　　者：林晓芹 邵仲杨 孙静[1] LIN Xiaoqin;SHAO Zhongyang;SUN Jing(Department of Ophthalmology,Bengbu Hospital of Shanghai General Hospital(the Second Affiliated Hospital of Bengbu Medical University),Bengbu 233000,Anhui,China)

机构地区：[1]上海市第一人民医院蚌埠医院(蚌埠医科大学第二附属医院)眼科,安徽蚌埠233000

出　　处：《糖尿病新世界》2024年第19期186-189,共4页Diabetes New World

摘　　要：目的探究糖尿病性黄斑水肿(diabetic macular edema,DME)患者应用康柏西普玻璃体内注射的临床疗效。方法选取2022年1月—2024年6月上海市第一人民医院蚌埠医院收治的60例DME患者为研究对象,根据不同治疗方式分为常规组(n=30,雷珠单抗玻璃体内注射)、观察组(n=30,康柏西普玻璃体内注射)。比较两组临床疗效、不良反应发生情况及临床指标。结果观察组治疗总有效率高于常规组,不良反应发生率低于常规组,差异有统计学意义(P均<0.05)。治疗3个月后,观察组黄斑中心凹视网膜厚度、最佳矫正视力水平优于常规组,差异有统计学意义(P均<0.05)。治疗3个月后,两组眼压水平比较,差异无统计学意义(P>0.05)。结论康柏西普应用于DME患者治疗可提高临床疗效,降低不良反应发生风险,并改善黄斑中心凹视网膜厚度、提高最佳矫正视力水平。Objective To explore the clinical efficacy of intravitreal injection of conbercept in patients with diabetic macular edema(DME).Methods A total of 60 patients with DME admitted to Bengbu Hospital of Shanghai General Hospital from January 2022 to June 2024 were selected as the study objects and divided into routine group(n=30,intravitreal injection of ranibizumab)and observation group(n=30,intravitreal injection of conbercept)according to different treatment methods.The clinical efficacy,adverse reactions and clinical indicators were compared between the two groups.Results The total effective rate of the observation group was higher than that of the routine group,and the incidence of adverse reactions was lower than that of the routine group,the differences were statistically significant(both P<0.05).After 3 months of treatment,the central macular thickness and best corrected visual acuity of the observation group were better than those of the routine group,and the differences were statistically significant(both P<0.05).After 3 months of treatment,there was no significant difference in intraocular pressure between the two groups(P>0.05).Conclusion The application of conbercept in the treatment of DME patients can improve the clinical efficacy,reduce the risk of adverse reactions,and improve the central macular thickness and best corrected visual acuity.

关 键 词：糖尿病性黄斑水肿 康柏西普 临床疗效 黄斑中心凹视网膜厚度 视力 

分 类 号：R587.1[医药卫生—内分泌]